Results 71 to 80 of about 10,726 (197)

CYP2C8 polymorphisms among malaria patients in Guinea-Bissau

, 2008
Tese mest. , Gestão da Água e da Costa, 2008, Universidade do AlgarveCytochrome P450 (CYP) 2C8 is the major enzyme responsible for the metabolism of many clinically important drugs including the antimalarial amodiaquine (AQ).
J-Lyn, Yvonne Knoo
core   +1 more source

Distribution of human CYP2C8*2 allele in three different African populations

Malaria Journal, 2012
Background The aim of this study was to investigate cytochrome P450 2C8*2 (CYP2C8*2) distribution and allele frequency in three populations from West and East Africa exposed to Plasmodium falciparum malaria. CYP2C8 enzyme is involved in the metabolism of
Paganotti Giacomo M, Gramolelli Silvia, Tabacchi Francesca, Russo Gianluca, Modiano David, Coluzzi Mario, Romano Rita   +6 more
doaj   +1 more source

Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American ...
Trevor N. Johnson, Fiskani Kondowe, Joyce van der Heijden, Saskia N. de Wildt, Iain Gardner, Karen Rowland Yeo   +5 more
wiley   +1 more source

The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro [PDF]

, 2009
The cytochrome P450 enzyme CYP2C8 appears to have a major role in pioglitazone metabolism. The present study was conducted to further clarify the role of individual CYPs and of the CYP2C8/9 polymorphisms in the primary metabolism of pioglitazone in vitro.
Zanger, U, Fuhr, U, Alexander Jetter, Jetter, A, Lal, J, Eugen Muschler, Muschler, E, Kirchheiner, J, Uwe Fuhr, Zadoyan, G, Anke Rattay, Julia Kirchheiner, Rattay, A, Jawahar Lal, Ulrich Zanger, Gregor Zadoyan   +15 more
core   +1 more source

Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Tuberculosis (TB) treatment requires long‐term multidrug regimens where dosing, efficacy, and safety optimization remain challenging. This tutorial establishes an integrated, open‐source, modular framework connecting high‐throughput PBPK (HT‐PBPK) simulations, mechanistic PBPK models, pharmacodynamic endpoints, and safety predictions for anti ...
Marco Siccardi, Nina Nauwelaerts, Raphaëlle Lesage, Diane Lefaudeux, Vanessa Baier, Venetia Karamitsou, Cleo Demeester, Miao‐Chan Huang, Alexander Kulesza, Stephan Schaller   +9 more
wiley   +1 more source

The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma

Cancer Medicine, 2018
Cytochrome P2C (CYP2C) subfamily members (CYP2C8, CYP2C9, CYP2C18, and CYP2C19) are known to participate in clinical drug metabolism. However, the association between CYP2C subfamily members and hepatocellular carcinoma (HCC) remains unclear.
Xiangkun Wang, Tingdong Yu, Xiwen Liao, Chengkun Yang, Chuangye Han, Guangzhi Zhu, Ketuan Huang, Long Yu, Wei Qin, Hao Su, Xiaoguang Liu, Tao Peng   +11 more
doaj   +1 more source

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source

Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population [PDF]

European Journal of Clinical Pharmacology, 2005
The purpose of the study was to study the distribution of poor and extensive metabolizers of CYP2C19 and CYP2D6 and to genotype for CYP2C8 and CYP2C9 among 312 randomly selected Faroese.The participants were phenotyped for CYP2D6 with the use of sparteine.
Halling, Jónrit, Petersen, Maria S., Damkier, Per, Nielsen, Flemming, Grandjean, Philippe, Weihe, Pal, Lundgren, Stefan, Lundblad, Mia Sandberg, Brøsen, Kim   +8 more
openaire   +4 more sources

The impact ofCYP2C8polymorphism and grapefruit juice on the pharmacokinetics of repaglinide [PDF]

British Journal of Clinical Pharmacology, 2005
AimsThe primary aim of the study was to investigate the possible effect of theCYP2C8*3allele and of grapefruit juice on the pharmacokinetics of repaglinide. Furthermore, the impact of a single dose of grapefruit juice on the pharmacokinetics of repaglinide in relation to dose.MethodsThirty‐six healthy male subjects, genotyped forCYP2C8*3(11 genotyped ...
Bidstrup, Tanja Busk, Damkier, Per, Olsen, A.K., Ekblom, M., Karlsson, A., Brøsen, Kim   +5 more
openaire   +3 more sources

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source